FGFR3 and central nervous system cancer: In 2017 Bielle et al. reported a series of 30 patients affected by FGFR3-TACC3-fused adult gliomas (age range: 42–87 years), which exhibited some unusual morphological features, combined with microcalcifications and desmoplasia; their cohort included 25 cases of GBMs, IDHwt, one case of gliosarcoma, IDHwt, one case of GBM, not otherwise specified, two cases of diffuse astrocytomas “with molecular features of GBM” (7p gain, 10q loss, and TERT promoter mutation) and one case of histological grade 2 diffuse astrocytoma, IDHwt with no additional molecular analyses available (14).